TraceLink Introduces New EU FMD Compliance Technology

TraceLink has unveiled an integrated Compliance and Digital Information Platform for pharmacies with EU Falsified Medicines Directive (FMD) requirements. The new mobile and web-based application enables any pharmacy in the EU to comply with verification and decommissioning requirements under the FMD while simultaneously delivering a real-time dashboard for business insights on medicine scans, expiry dates, dispensation trends, product inventory and more. The new platform was revealed at NEXUS 17 in Barcelona during the opening keynote session by TraceLink president and chief executive officer, Shabbir Dahod.

The new Pharmacy Compliance and Digital Information Platform provides a single destination for pharmacies to meet their EU FMD requirements, which take effect in February 2019. Pharmacists who use the application will also benefit from user-friendly dashboard analytics that provide insights from all transaction information that is captured within the application.

Pharmacists can also "opt in" to a service within the app that links them to participating pharmaceutical manufacturers, paving the way for a new digital communication channel designed to enhance the information-sharing between pharmaceutical companies and the healthcare providers who dispense their medications. Once they opt in, pharmacists will be able to receive specific and contextual pharmaceutical product information directly from the manufacturer, including details about indications, usage, best practices for product administration, and potential warnings and precautions.

"TraceLink has broken new ground with this application, addressing a critical information gap that has existed for decades between pharmaceutical companies, pharmacists and patients," said Mr. Dahod. "Our unique approach of connecting the entire pharmaceutical supply chain on an interoperable network makes TraceLink the only company capable of offering this type of solution and facilitating a new era of real-time information sharing that will transform how the industry provides care to patients. This is the first in a series of steps we are taking to augment our effort of eliminating counterfeit drugs from the global marketplace with applications that deliver tangible and meaningful value to an industry that serves hundreds of millions of people who depend on prescription medications to improve their health."